CLDF Title
Home | Contact Us | Bookmark
HEPATITIS
HBV HCV HDV
CIRRHOSIS
HEPATIC ENCEPHALOPATHY (HE) HEPATORENAL SYNDROME (HRS) THROMBOCYTOPENIA
NASH
CHOLESTATIC
PRIMARY BILIARY CHOLANGITIS (PBC)
HCC PEDIATRIC LIVER DISEASE
About CLDF
Board of Trustees Board of Advisors/Faculty 2020 GI Fellow Board of Advisors CLDF Committees
Centers of Educational Expertise  
Slide Library Webcasts Abstract Library Conference Highlights
 
PBC | Abstract Library
Abstract Library
 
The summaries are free for public use. The Chronic Liver Disease Foundation will continue to add and archive summaries of articles deemed relevant to CLDF by the Board of Trustees and its Advisors.
1.The Management of Cholestatic Liver Diseases: Current Therapies and Emerging New Possibilities
 

J Clin Med. 2021 Apr 18;10(8):1763. doi: 10.3390/jcm10081763.

Marta Mazzetti 1 2, Giulia Marconi 1, Martina Mancinelli 1, Antonio Benedetti 1, Marco Marzioni 1, Luca Maroni 1
 
2.Membranous nephropathy and primary biliary cholangitis: A case report and review of the literature
 

Clin Nephrol. 2021 Apr 26. doi: 10.5414/CN110363. Online ahead of print.

Jonas Zimmermann, Sigrid Harendza, Mercedes Noriega, Linda Reinhard, Elion Hoxha
 
3.Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis
 

J Hepatol. 2021 Apr 18;S0168-8278(21)00245-2. doi: 10.1016/j.jhep.2021.04.010.Online ahead of print.

Atsushi Tanaka 1, Junko Hirohara 2, Toshiaki Nakano 2, Kosuke Matsumoto 3, Olivier Chazouillères 4, Hajime Takikawa 5, Bettina E Hansen 6, Fabrice Carrat 7, Christophe Corpechot 8
 
4.Short Chain Fatty Acid and Fecal Microbiota Profiles Are Linked to Fibrosis in Primary Biliary Cholangitis
 

FEMS Microbiol Lett. 2021 Apr 9;fnab038. doi: 10.1093/femsle/fnab038. Online ahead of print.

Craig Lammert 1, Andrea Shin 1, Huiping Xu 2, Christopher Hemmerich 3, Thomas M O'Connell 4, Naga Chalasani 1
 
5.Promyelocytic Leukemia Antigen Expression: a Histological Marker for Primary Biliary Cholangitis Diagnosis?
 

J Transl Int Med. 2021 Mar 31;9(1):43-51. doi: 10.2478/jtim-2021-0008. eCollection 2021 Mar.

Panagiotis A Papamichalis 1 2, Kalliopi Zachou 2, Roidoula A Papamichali 1, Maria Ioannou 1, Nikolaos K Gatselis 2, George N Dalekos 2, George K Koukoulis 1
 
6.Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis
 

Aliment Pharmacol Ther. 2021 Mar 25. doi: 10.1111/apt.16336. Online ahead of print.

Pierre-Antoine Soret 1, Laurent Lam 1, Fabrice Carrat 1, Lena Smets 2, Thomas Berg 3, Marco Carbone 4, Pietro Invernizzi 4, Vincent Leroy 5, Palak Trivedi 6, Nora Cazzagon 7, Christina Weiler-Normann 8, Laurent Alric 9, Isabelle Rosa-Hezode 10, Alexandra Heurgué 11, Jean-Paul Cervoni 12, Jérôme Dumortier 13, Pascal Potier 14, Olivier Roux 15, Christine Silvain 16, Christophe Bureau 9, Rodolphe Anty 17, Dominique Larrey 18, Cynthia Levy 19, Albert Pares 20, Christoph Schramm 8, Frederik Nevens 2, Olivier Chazouillères 1, Christophe Corpechot 1
 
7.Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis
 

Aliment Pharmacol Ther. 2021 Mar 25. doi: 10.1111/apt.16336. Online ahead of print.

Pierre-Antoine Soret 1, Laurent Lam 1, Fabrice Carrat 1, Lena Smets 2, Thomas Berg 3, Marco Carbone 4, Pietro Invernizzi 4, Vincent Leroy 5, Palak Trivedi 6, Nora Cazzagon 7, Christina Weiler-Normann 8, Laurent Alric 9, Isabelle Rosa-Hezode 10, Alexandra Heurgué 11, Jean-Paul Cervoni 12, Jérôme Dumortier 13, Pascal Potier 14, Olivier Roux 15, Christine Silvain 16, Christophe Bureau 9, Rodolphe Anty 17, Dominique Larrey 18, Cynthia Levy 19, Albert Pares 20, Christoph Schramm 8, Frederik Nevens 2, Olivier Chazouillères 1, Christophe Corpechot 1
 
8.Autoimmune Hepatitis-Primary Biliary Cholangitis Overlap Syndrome Triggered by COVID-19
 

Eur J Case Rep Intern Med. 2021 Feb 4;8(3):002264. doi: 10.12890/2021_002264.eCollection 2021.

Balraj Singh 1, Parminder Kaur 2, Michael Maroules 1
 
9.Safety of fibrates in cholestatic liver diseases
 

Liver Int. 2021 Mar 9. doi: 10.1111/liv.14871. Online ahead of print.

Andres F Carrion 1, Keith D Lindor 2, Cynthia Levy 3
 
10.Accuracy of Transient Elastography in assessing fibrosis at diagnosis in naïve patients with Primary Biliary Cholangitis: a dual cut-off approach
 

Hepatology. 2021 Mar 16. doi: 10.1002/hep.31810. Online ahead of print.

Laura Cristoferi 1 2 3, Vincenza Calvaruso 4, Diletta Overi 5, Mauro Viganò 6, Cristina Rigamonti 7, Elisabetta Degasperi 8, Vincenzo Cardinale 9, Sara Labanca 10, Nicola Zucchini 11, Anna Fichera 4, Vito Di Marco 4, Monica Leutner 12, Rosanna Venere 13, Antonino Picciotto 10, Martina Lucà 1 2, Giacomo Mulinacci 1 2, Andrea Palermo 1 2, Alessio Gerussi 1 2, Daphne D'Amato 1 2, Sarah Elisabeth O'Donnell 1 2, Federica Cerini 6, Carla De Benedittis 7, Federica Malinverno 1 2, Vincenzo Ronca 1 2, Clara Mancuso 1 2, Nora Cazzagon 14, Antonio Ciaccio 1 2, Donatella Barisani 1, Marco Marzioni 15, Annarosa Floreani 16 17, Domenico Alvaro 9, Eugenio Gaudio 5, Pietro Invernizzi 1 2, Guido Carpino 18, Alessandra Nardi 19, Marco Carbone 1 2, behalf of the Italian PBC Registry
 
11.Real-world experience with obeticholic acid in patients with primary biliary cholangitis
 

JHEP Rep. 2021 Jan 27;3(2):100248. doi: 10.1016/j.jhepr.2021.100248. eCollection 2021 Apr.

Daphne D'Amato 1, Antonio De Vincentis 2, Federica Malinverno 1, Mauro Viganò 3, Domenico Alvaro 4, Maurizio Pompili 5, Antonino Picciotto 6, Valeria Pace Palitti 7, Maurizio Russello 8, Silvia Storato 9, Marie Graciella Pigozzi 10, Vincenza Calvaruso 11, Elisabetta De Gasperi 12, Ana Lleo 13, Antonino Castellaneta 14, Adriano Pellicelli 15, Nora Cazzagon 16, Annarosa Floreani 16, Luigi Muratori 17, Stefano Fagiuoli 18, Grazia Anna Niro 19, Valentina Feletti 20, Raffaele Cozzolongo 21, Natalia Terreni 22, Marco Marzioni 23, Rinaldo Pellicano 24, Pietro Pozzoni 25, Leonardo Baiocchi 26, Luchino Chessa 27, Floriano Rosina 28, Gaetano Bertino 29, Maria Vinci 30, Anna Morgando 24, Ester Vanni 24, Gaetano Scifo 31, Rodolfo Sacco 32, Maria D'Antò 33, Valentina Bellia 34, Roberto Boldizzoni 35, Silvia Casella 36, Barbara Omazzi 37, Guido Poggi 38, Laura Cristoferi 1, Alessio Gerussi 1, Vincenzo Ronca 1, Rosanna Venere 4, Francesca Ponziani 5, Maria Cannavò 8, Alessandro Mussetto 20, Rosanna Fontana 19, Francesco Losito 21, Evelise Frazzetto 29, Marco Distefano 31, Francesca Colapietro 13, Sara Labanca 6, Giulia Marconi 23, Giuseppe Grassi 26, Giovanni Galati 2, Sarah Elizabeth O'Donnell 1, Clara Mancuso 1, Giacomo Mulinacci 1, Andrea Palermo 1, Ernesto Claar 39, Antonio Izzi 40, Antonio Picardi 2, Pietro Invernizzi 1, Marco Carbone 1, Umberto Vespasiani-Gentilucci 2, Italian PBC Registry and the Club Epatologi Ospedalieri (CLEO)/Associazione Italiana Gastroenterologi ed Endoscopisti Digestivi Ospedalieri (AIGO) PBC Study Group
 
12.Home-based exercise in patients with refractory fatigue associated with primary biliary cholangitis: a protocol for the EXerCise Intervention in cholesTatic LivEr Disease (EXCITED) feasibility trial
 

BMJ Open Gastroenterol. 2021 Mar;8(1):e000579. doi: 10.1136/bmjgast-2020-000579.

Alice Freer 1 2, Felicity Williams 1 3, Simon Durman 4, Jennifer Hayden 2, Palak J Trivedi # 5 2 6, Matthew J Armstrong # 2
 
13.X chromosome contribution to the genetic architecture of primary biliary cholangitis
 

Gastroenterology. 2021 Mar 3;S0016-5085(21)00466-2. doi: 10.1053/j.gastro.2021.02.061.Online ahead of print.

 

Gastroenterology. 2021 Mar 3;S0016-5085(21)00466-2. doi: 10.1053/j.gastro.2021.02.061.Online ahead of print.

Rosanna Asselta 1, Elvezia Maria Paraboschi 1, Alessio Gerussi 2, Heather J Cordell 3, George F Mells 4, Richard N Sandford 4, David E Jones 5, Minoru Nakamura 6, Kazuko Ueno 7, Yuki Hitomi 8, Minae Kawashima 8, Nao Nishida 8, Katsushi Tokunaga 9, Masao Nagasaki 10, Atsushi Tanaka 11, Ruqi Tang 12, Zhiqiang Li 13, Yongyong Shi 13, Xiangdong Liu 14, Ma Xiong 12, Gideon Hirschfield 15, Katherine A Siminovitch 16, Canadian-US PBC Consortium; Italian PBC Genetics Study Group; UK-PBC Consortium; Japan PBC-GWAS Consortium; Marco Carbone 2, Giulia Cardamone 1, Stefano Duga 1, M Eric Gershwin 17, Michael F Seldin 17, Pietro Invernizzi 18
 
14.Quality of life in patients with primary biliary cholangitis: A cross-geographical comparison
 

J Transl Autoimmun. 2021 Jan 6;4:100081. doi: 10.1016/j.jtauto.2021.100081. eCollection 2021.

Lorenzo Montali 1, Andrea Gragnano 1, Massimo Miglioretti 1, Alessandra Frigerio 1, Luca Vecchio 1, Alessio Gerussi 2 3, Laura Cristoferi 2 3, Vincenzo Ronca 2 3, Daphne D'Amato 2 3, Sarah Elizabeth O'Donnell 2 3, Clara Mancuso 2 3, Martina Lucà 2 3, Minami Yagi 4, Anna Reig 5, Laura Jopson 6, Sesé Pilar 5, Dave Jones 6, Albert Pares 5, George Mells 7, Atsushi Tanaka 4, Marco Carbone 2 3, Pietro Invernizzi 2 3
 
15.Burden of Primary Biliary Cholangitis Among Inpatient Population in the United States
 

Hepatol Commun. 2019 Jan 28;3(3):356-364. doi: 10.1002/hep4.1314. eCollection 2019 Mar.

Omer Shahab 1, Mehmet Sayiner 1, James Paik 2, Sean Felix 2, Pegah Golabi 2, Zobair M Younossi 1 2
 
16.Investigational drugs in early phase development for primary biliary cholangitis
 

Expert Opin Investig Drugs. 2021 Feb;30(2):131-141. doi: 10.1080/13543784.2021.1857364.Epub 2020 Dec 11.

Eric M Gochanour 1, Kris V Kowdley 1
 
17.Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis
 

Clin Gastroenterol Hepatol. 2020 Aug 7;S1542-3565(20)31083-1.doi: 10.1016/j.cgh.2020.08.006. Online ahead of print.

Alessio Gerussi 1, Davide Paolo Bernasconi 2, Sarah Elisabeth O'Donnell 1, Willem J Lammers 3, Henk Van Buuren 3, Gideon Hirschfield 4, Harry Janssen 4, Christophe Corpechot 5, Anna Reig 6, Albert Pares 6, Pier Maria Battezzati 7, Massimo Giovanni Zuin 7, Nora Cazzagon 8, Annarosa Floreani 9, Frederik Nevens 10, Nikolaos Gatselis 11, George Dalekos 11, Marlyn J Mayo 12, Douglas Thorburn 13, Tony Bruns 14, Andrew L Mason 15, Xavier Verhelst 16, Kris Kowdley 17, Adriaan van der Meer 3, Grazia Anna Niro 18, Benedetta Terziroli Beretta-Piccoli 19, Marco Marzioni 20, Luca Saverio Belli 21, Fabio Marra 22, Maria Grazia Valsecchi 2, Keith D Lindor 23, Pietro Invernizzi 1, Bettina E Hansen 24, Marco Carbone 25, Italian PBC Study Group and the GLOBAL PBC Study Group
 
18.Simplified care-pathway selection for nonspecialist practice: the GLOBAL Primary Biliary Cholangitis Study Group Age, Bilirubin, Alkaline phosphatase risk assessment tool
 

Eur J Gastroenterol Hepatol. 2020 Dec 14. doi: 10.1097/MEG.0000000000002029.Online ahead of print.

Carla F Murillo Perez 1 2, Aliya Gulamhusein 1, Marco Carbone 3 4, Palak J Trivedi 5, Adriaan J van der Meer 2, Christophe Corpechot 6, Pier Maria Battezzati 7, Willem J Lammers 2, Nora Cazzagon 4 8, Annarosa Floreani 4 8, Albert Parés 9, Frederik Nevens 10, Ana Lleo 11, Marlyn J Mayo 12, Kris V Kowdley 13, Cyriel Y Ponsioen 14, George N Dalekos 15, Nikolaos K Gatselis 15, Douglas Thorburn 16, Andrew L Mason 17, Harry Janssen 1, Xavier Verhelst 4 18, Tony Bruns 19, Keith D Lindor 20, Olivier Chazouillères 6, Pietro Invernizzi 3 4, Bettina E Hansen 1 21, Gideon M Hirschfield 1, GLOBAL PBC Study Group
 
19.Utility of palliative EUS-guided biliary drainage using lumen-apposing metal stents: a prospective multicenter feasibility study (with video)
 

Gastrointest Endosc. 2021 Feb 2;S0016-5107(21)00090-0. doi: 10.1016/j.gie.2021.01.029.Online ahead of print.

Suresh Vasan Venkatachalapathy 1, Martin W James 1, Matthew Huggett 2, Bharat Paranandi 2, Stephen P Pereira 3, Gavin Johnson 4, Aloysious D Aravinthan 5, Guruprasad P Aithal 5
 
20.Is UDCA really a post-transplant panacea?
 

Liver Transpl. 2021 Jan 19. doi: 10.1002/lt.25989. Online ahead of print.

Cynthia Levy 1, Shahnaz Sultan 2
 
21.Geo-epidemiology and environmental co-variate mapping of primary biliary cholangitis and primary sclerosing cholangitis
 

JHEP Rep. 2020 Nov 4;3(1):100202. doi: 10.1016/j.jhepr.2020.100202. eCollection 2021 Feb.

Jessica Katharine Dyson 1 2, Alasdair Blain 3, Mark David Foster Shirley 4, Mark Hudson 1 2, Steven Rushton 4, David Emrys Jeffreys Jones 1 2
 
22.A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA
 

J Hepatol. 2021 Jan 20;S0168-8278(21)00022-2. doi: 10.1016/j.jhep.2021.01.013.Online ahead of print.

Jörn M Schattenberg 1, Albert Pares 2, Kris V Kowdley 3, Michael A Heneghan 4, Stephen Caldwell 5, Daniel Pratt 6, Alan Bonder 7, Gideon M Hirschfield 8, Cynthia Levy 9, John Vierling 10, David Jones 11, Anne Tailleux 12, Bart Staels 12, Sophie Megnien 13, Remy Hanf 13, David Magrez 13, Pascal Birman 13, Velimir Luketic 14
 
23.Experimental Pharmacological Agents for the Treatment of Primary Biliary Cholangitis
 

J Exp Pharmacol. 2020 Dec 17;12:643-652. doi: 10.2147/JEP.S267375.eCollection 2020.

Annarosa Floreani 1 2
 
24.Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitis
 

JHEP Rep. 2020 Sep 29;3(1):100191. doi: 10.1016/j.jhepr.2020.100191. eCollection 2021 Feb.

Maren H Harms 1, Gideon M Hirschfield 2, Annarosa Floreani 3, Marlyn J Mayo 4, Albert Parés 5, Alexander Liberman 6, Elizabeth Smoot Malecha 6, Richard Pencek 6, Leigh MacConell 6, Bettina E Hansen 2 7
 
25.Primary biliary cholangitis
 

Lancet. 2020 Dec 12;396(10266):1915-1926. doi: 10.1016/S0140-6736(20)31607-X.

Ana Lleo 1, Giu-Qiang Wang 2, Merrill Eric Gershwin 3, Gideon M Hirschfield 4
 
26.Portal hypertension in primary biliary cholangitis: prevalence, natural history and histological correlates
 

Eur J Gastroenterol Hepatol. 2020 Dec 14. doi: 10.1097/MEG.0000000000002033.Online ahead of print.

Thomas W Warnes 1, Stephen A Roberts 2, Alexander Smith 1, Victor M Cope 3, Patricia Vales 4, Najib Y Haboubi 5, Raymond F McMahon 6
 
27.UDCA Decreases Incidence of Primary Biliary Cholangitis and Biliary Complications after Liver Transplant: A Meta-Analysis
 

Liver Transpl. 2020 Nov 13. doi: 10.1002/lt.25935. Online ahead of print.

Mark R Pedersen 1, Garrett Greenan 2, Sumant Arora 3, Arvind Murali 3, Marlyn J Mayo 1
 
28.Primary Sclerosing Cholangitis and Primary Biliary Cirrhosis Overlap Syndrome: A Review
 

J Clin Transl Hepatol. 2020 Sep 28;8(3):336-346. doi: 10.14218/JCTH.2020.00036.Epub 2020 Aug 24.

Sheena Mago 1, George Y Wu 1
 
29.Fibrates for itch (FITCH) in fibrosing cholangiopathies: a double blind, randomized, placebo-controlled trial
 

Gastroenterology. 2020 Oct 5;S0016-5085(20)35226-4. doi:10.1053/j.gastro.2020.10.001.Online ahead of print.

Elsemieke de Vries 1, Ruth Bolier 1, Jorn Goet 2, Albert Parés 3, Jef Verbeek 4, Marleen de Vree 5, Joost Drenth 6, Karel van Erpecum 7, Karin van Nieuwkerk 8, Frans van der Heide 5, Nahid Mostafavi 1, Jeltje Helder 1, Cyriel Ponsioen 1, Ronald Oude Elferink 1, Henk van Buuren 2, Ulrich Beuers 9, Netherlands Association for the Study of the Liver - Cholestasis Working Group
 
30. Genome-wide resolution peripheral blood methylome profiling reveals signatures for cholestatic liver disease
 

Epigenomics. 2020 Aug;12(16):1363-1375. doi: 10.2217/epi-2020-0048. Epub 2020 Sep 11.

Raymond M Moore 1, Zhifu Sun 1, Brian D Juran 2, Konstantinos N Lazaridis 2
 
31.A placebo-controlled randomised trial of budesonide for primary biliary cholangitis following an insufficient response to UDCA
 

J Hepatol. 2020 Sep 17;S0168-8278(20)33623-0. doi: 10.1016/j.jhep.2020.09.011.Online ahead of print.

G M Hirschfield 1, U Beuers 2, L Kupcinskas 3, P Ott 4, A Bergquist 5, M Färkkilä 6, M P Manns 7, A Parés 8, U Spengler 9, M Stiess 10, R Greinwald 10, M Pröls 10, D Wendum 11, U Drebber 12, R Poupon 13
 
32.Liver Stiffness Measured by Either Magnetic Resonance or Transient Elastography Is Associated With Liver Fibrosis and Is an Independent Predictor of Outcomes Among Patients With Primary Biliary Cholangitis
 

J Clin Gastroenterol. 2020 Sep 23. doi: 10.1097/MCG.0000000000001433. Online ahead of print.

Karim T Osman 1, Daniel B Maselli 1, Ilkay S Idilman 2, Daniel J Rowan 3, Jason K Viehman 4, William S Harmsen 4, Denise M Harnois 5, Elizabeth J Carey 6, Andrea A Gossard 1, Nicholas F LaRusso 1, Keith D Lindor 6, Sudhakar K Venkatesh 2, John E Eaton 1
 
33.An update on the management of cholestatic liver diseases
 

Clin Med (Lond). 2020 Sep;20(5):513-516. doi: 10.7861/clinmed.2020-0697.

Gautham Appanna 1, Yiannis Kallis 2
 
34.Review article: pathophysiology and management of primary biliary cholangitis
 

Aliment Pharmacol Ther. 2020 Aug 19. doi: 10.1111/apt.16023. Online ahead of print.

Kristel K Leung 1 2, Maya Deeb 1 2, Gideon M Hirschfield 1 2
 
35.Prevalence and long-term outcome of sub-clinical primary sclerosing cholangitis in patients with ulcerative colitis
 

Liver Int. 2020 Aug 25. doi: 10.1111/liv.14645. Online ahead of print.

Emma L Culver 1, Helen K Bungay 2, Margaret Betts 2, Colm Forde 2 3, Otto Buchel 4, Charis Manganis 1, Bryan F Warren 5, Jr Fraser Cummings 1 6, Satish Keshav 1, Simon P L Travis 1, Roger W Chapman 1
 
36.Role of Antinuclear Antibodies in Primary Biliary Cholangitis
 

Am J Gastroenterol. 2020 Jul 22. doi: 10.14309/ajg.0000000000000765. Online ahead of print.

Cynthia Levy 1, Christopher L Bowlus 2
 
37.Reevaluating Goals of Therapy in Primary Biliary Cholangitis: Is Good Enough Is Not Good Enough Anymore?
 

Am J Gastroenterol. 2020 Jul;115(7):1024-1025. doi: 10.14309/ajg.0000000000000693.

Richard J Bower 1, Catherine Frenette 2
 
38.Cholangiocarcinoma: Diagnosis and Management
 

Clin Liver Dis. 2020 Aug;24(3):421-436. doi: 10.1016/j.cld.2020.04.005.Epub 2020 May 29.

Adam P Buckholz 1, Robert S Brown Jr 2
 
39.Gut microbiome in primary sclerosing cholangitis: A review
 

World J Gastroentero. 2020 Jun 7;26(21):2768-2780.doi: 10.3748/wjg.v26.i21.2768.

Rebecca Little 1, Eytan Wine 2, Binita M Kamath 1, Anne M Griffiths 1, Amanda Ricciuto 3
 
40.How Much Liver Tissue Is Required for Sufficient Histological Staging in Patients With Primary Biliary Cholangitis?
 

Digestion. 2020 Jun 3;1-9. doi: 10.1159/000507392. Online ahead of print.

Marcel Vetter 1, Andreas E Kremer 1, Abbas Agaimy 2, Lukas Pfeifer 1, Markus F Neurath 1, Jürgen Siebler 1, Steffen Zopf 3 4
 
41.Effects of Primary Biliary Cholangitis on Quality of Life and Health Care Costs in the United Kingdom
 

Clin Gastroenterol Hepatol. 2020 Jun 17;S1542-3565(20)30836-3.doi: 10.1016/j.cgh.2020.06.025. Online ahead of print.

Stephen Rice 1, Viviana Albani 2, Dimitrios Minos 3, Gulnar Fattakhova 2, George F Mells 4, Marco Carbone 4, Steven Flack 4, Nikoletta Varvaropoulou 4, Jonathan Badrock 4, Ann Spicer 4, Richard N Sandford 4, Mark D F Shirley 5, Diarmuid Coughlan 2, Gideon Hirschfield 6, Simon D Taylor-Robinson 7, UK-PBC Consortium; Luke Vale 2, David E J Jones 8
 
42.Risk Factors for Complications After Cholecystectomy for Common Bile Duct Stones: An EAST Multicenter Study
 

Surgery. 2020 Jul;168(1):62-66. doi: 10.1016/j.surg.2020.04.011. Epub 2020 May 26.

Brett M Tracy 1, Cameron W Paterson 2, Denise M Torres 3, Katelyn Young 3, Beth R Hochman 4, Martin D Zielinski 5, Sigrid K Burruss 6, Michelle B Mulder 7, Daniel Dante Yeh 7, Rondi B Gelbard 2, EAST Retained Common Bile Duct Stones Study Group

  • EAST Retained Common Bile Duct Stones Study Group: 

Beth Hochman, Natasha Coleman, Anna Goldenberg-Sandau, Jennifer Schweinsburg, Rondi Gelbard, Cameron Paterson, Brett Tracy, Rondi Gelbard, Cameron Paterson, Brett Tracy, Katelyn Young, Denise Torres, David Morris, Ashley Boyer, Sigrid Burruss, Xian Luo-Owen, Daniel Cullinane, Laura Cullinane, April Mendoza, Apostolos Gaitanidis, Martin Zielinski, Maraya Camazine, Shaneeta Johnson, Michelle Mulder, Rishi Rattan, D Dante Yeh, Jonathan Saxe, Daniel Kinstedt, Amanda Celii, Kiran Venincasa
 
43.Obeticholic Acid-A New Therapy in PBC and NASH
 

B Med Bull. 2020 May 15;133(1):95-104. doi: 10.1093/bmb/ldaa006.

Roger W Chapman 1 2, Kate D Lynch 1 2 3 4
 
44.Emerging Drugs for the Treatment of Primary Biliary Cholangitis
 

Expert Opin Emerg Drugs. 2020 Jun;25(2):101-112. doi: 10.1080/14728214.2020.1751814.Epub 2020 May 5.

Naw April Phaw 1 2, Jessica Katharine Dyson 1 2, David Jones 1 2 3
 
45.Pregnancy Outcomes in Women With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: A Retrospective Cohort Study
 

BJOG. 2020 Jun;127(7):876-884. doi: 10.1111/1471-0528.16119. Epub 2020 Mar 8.

M Cauldwell 1, F L Mackie 2, P J Steer 1, M A Henehghan 3, J H Baalman 4, J Brennand 5, T Johnston 2, S Dockree 6, C Hedley 7, S Jarvis 8, S Khan 9, F M McAuliffe 4, L Mackillop 6, L Penna 7, B Smith 10, P Trivedi 9, S Verma 11 12, R Westbrook 13, S Winifield 14, C Williamson 15
 
46.Osteoporosis in Primary Biliary Cholangitis: Prevalence, Impact and Management Challenges
 

Clin Exp Gastroenterol. 2020 Jan 15;13:17-24. doi: 10.2147/CEG.S204638.eCollection 2020.

Hirsh D Trivedi 1, Christopher J Danford 1, Daniela Goyes 1, Alan Bonder 1
 
47.Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase
 

Am J Gastroenterol. 2020 Feb 20. doi: 10.14309/ajg.0000000000000557. Online ahead of print.

Carla F Murillo Perez 1 2, Maren H Harms 2, Keith D Lindor 3, Henk R van Buuren 2, Gideon M Hirschfield 1, Christophe Corpechot 4, Adriaan J van der Meer 2, Jordan J Feld 1, Aliya Gulamhusein 1, Willem J Lammers 2, Cyriel Y Ponsioen 5, Marco Carbone 6, Andrew L Mason 7, Marlyn J Mayo 8, Pietro Invernizzi 6, Pier Maria Battezzati 9, Annarosa Floreani 10, Ana Lleo 11, Frederik Nevens 12, Kris V Kowdley 13, Tony Bruns 14 15, George N Dalekos 16, Nikolaos K Gatselis 16, Douglas Thorburn 17, Palak J Trivedi 18, Xavier Verhelst 19, Albert Parés 20, Harry L A Janssen 1, Bettina E Hansen 1 21, GLOBAL PBC Study Group
 
48.A Clinical Review of Primary Biliary Cholangitis
 

Gastroenterol Nurs. Mar/Apr 2020;43(2):E48-E55. doi: 10.1097/SGA.0000000000000480.

Richard Pullen 1
 
49.Ursodeoxycholic Acid Treatment Preferentially Improves Overall Survival Among African Americans With Primary Biliary Cholangitis
 

Am J Gastroenterol. 2020 Feb;115(2):262-270. doi: 10.14309/ajg.0000000000000512.

Stuart C Gordon 1, Kuan-Han Hank Wu 2, Keith Lindor 3, Christopher L Bowlus 4, Carla V Rodriguez 5 6, Heather Anderson 7, Joseph A Boscarino 8, Sheri Trudeau 2, Loralee B Rupp 9, Irina V Haller 10, Robert J Romanelli 11, Jeffrey J VanWormer 12, Mark A Schmidt 13, Yihe G Daida 14, Amandeep Sahota 15, Jennifer Vincent 16, Talan Zhang 1, Jia Li 1, Mei Lu 1, FOLD Investigators
 
50.Diagnosis and Management of Primary Biliary Cholangitis
 

Am J Gastroenterol. 2019 Jan;114(1):48-63. doi: 10.1038/s41395-018-0390-3.

Zobair M Younossi 1, David Bernstein 2, Mitchell L Shiffman 3, Paul Kwo 4, W Ray Kim 5, Kris V Kowdley 6, Ira M Jacobson 7
 
51.Characteristics and Outcomes of Liver Transplantation for Primary Biliary Cholangitis in Young Patients: Analysis of the United Network for Organ Sharing Database
 

Transplantation. 2019 Jun;103(6):1191-1198. doi: 10.1097/TP.0000000000002501.

Amandeep Singh 1, Danielle Fritze 2, Mahsa Mansouri 3, Rocio Lopez 4, Fred Poordad 2 3, Eric Lawitz 2 3, Francisco Cigarroa 2, Glen Halff 2, Naim Alkhouri 3
 
52.Pruritus Is Common and Undertreated in Patients With Primary Biliary Cholangitis in the United Kingdom
 

Clin Gastroenterol Hepatol. 2019 Jun;17(7):1379-1387.e3. doi: 10.1016/j.cgh.2018.12.007.Epub 2018 Dec 14.

Vinod S Hegade 1, George F Mells 2, Holly Fisher 3, Stuart Kendrick 4, Julia DiBello 5, Kim Gilchrist 5, Graeme J Alexander 2, Gideon M Hirschfield 6, Richard N Sandford 7, David E J Jones 8, UK-PBC Consortium
 
53.Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis
 

Gastroenterol Hepatol. 2019 Sep;17(10):2076-2084.e2. doi: 10.1016/j.cgh.2018.12.028.Epub 2019 Jan 4.

Angela C Cheung 1, Willem J Lammers 2, Carla F Murillo Perez 3, Henk R van Buuren 2, Aliya Gulamhusein 3, Palak J Trivedi 4, Konstantinos N Lazaridis 1, Cyriel Y Ponsioen 5, Annarosa Floreani 6, Gideon M Hirschfield 3, Christophe Corpechot 7, Marlyn J Mayo 8, Pietro Invernizzi 9, Pier Maria Battezzati 10, Albert Parés 11, Frederik Nevens 12, Douglas Thorburn 13, Andrew L Mason 14, Marco Carbone 9, Kris V Kowdley 15, Tony Bruns 16, George N Dalekos 17, Nikolaos K Gatselis 17, Xavier Verhelst 18, Keith D Lindor 19, Ana Lleo 9, Raoul Poupon 7, Harry L A Janssen 3, Bettina E Hansen 20, Global PBC Study Group
 
54.Primary Biliary Cholangitis in Medicare Population: The Impact on Mortality and Resource Use
 

Hepatology. 2019 Jan;69(1):237-244. doi: 10.1002/hep.30174.

Mehmet Sayiner 1 2, Pegah Golabi 1, Maria Stepanova 3, Issah Younossi 3, Fatema Nader 3, Andrei Racila 2 3, Zobair M Younossi 1 2
 
55.Primary Biliary Cholangitis in Medicare Population: The Impact on Mortality and Resource Utilization
  Sayiner M1,2, Golabi P1, Stepanova M3, Younossi I3, Nader F3, Racila A2,3, Younossi ZM1,2. Hepatology. 2018 Jul 17. doi: 10.1002/hep.30174. [Epub ahead of print]
 
56.Alcohol and Obesity: A Dangerous Association for Fatty Liver Disease
  Mahli A1, Hellerbrand C. Dig Dis. 2016;34 Suppl 1:32-9. doi: 10.1159/000447279. Epub 2016 Aug 22.
 
57.Discrimination of Nonalcoholic Steatohepatitis Using Transient Elastography in Patients with Nonalcoholic Fatty Liver Disease
  Lee HW1, Park SY2, Kim SU1, Jang JY3, Park H4, Kim JK1, Lee CK5, Chon YE1, Han KH1. PLoS One. 2016 Jun 10;11(6):e0157358. doi: 10.1371/journal.pone.0157358. eCollection 2016.
 
58.Formulation for Effective Screening and Management of Nonalcoholic Steatohepatitis: Noninvasive NAFLD Management Strategy
  Hirose K1, Kanefuji T2, Suda T2, Sugitani S3, Nagasaki K4, Kubota T5, Igarashi M1, Terai S1. Gastroenterol Res Pract. 2016;2016:6343656. doi: 10.1155/2016/6343656. Epub 2016 Jun 13.
 
59.The impact of body weight gain on nonalcoholic fatty liver disease and metabolic syndrome during earlier and later adulthood
  Du S1, Wang C2, Jiang W3, Li C4, Li Y1, Feng R5, Sun C6. Diabetes Res Clin Pract. 2016 Jun;116:183-91. doi: 10.1016/j.diabres.2016.04.047. Epub 2016 Apr 30.
 
60.The Association between Non-Invasive Hepatic Fibrosis Markers and Cardiometabolic Risk Factors in the Framingham Heart Study
  Long MT1,2, Pedley A2,3, Massaro JM2,4, Hoffmann U5, Fox CS2,6. PLoS One. 2016 Jun 24;11(6):e0157517. doi: 10.1371/journal.pone.0157517. eCollection 2016.
 
61.Nonalcoholic fatty liver disease and obstructive sleep apnea
  Aron-Wisnewsky J1, Clement K2, Pépin JL3. Metabolism. 2016 Aug;65(8):1124-35. doi: 10.1016/j.metabol.2016.05.004. Epub 2016 May 13.
 
62.Host factors are dominant in the development of post-liver transplant non-alcoholic steatohepatitis
  Boga S1, Munoz-Abraham AS1, Rodriguez-Davalos MI1, Emre SH1, Jain D1, Schilsky ML1. World J Hepatol. 2016 May 28;8(15):659-64. doi: 10.4254/wjh.v8.i15.659.
 
63.Non-alcoholic fatty liver disease and dyslipidemia: An update
  Katsiki N1, Mikhailidis DP2, Mantzoros CS3.Author information Metabolism. 2016 May 13. pii: S0026-0495(16)30018-X. doi: 10.1016/j.metabol.2016.05.003. [Epub ahead of print]
 
64.The Natural Course of Non-Alcoholic Fatty Liver Disease
  Calzadilla Bertot L1, Adams LA2,3. Int J Mol Sci. 2016 May 20;17(5). pii: E774. doi: 10.3390/ijms17050774.
 
65.Lifestyle and Dietary Interventions in the Management of Nonalcoholic Fatty Liver Disease
  Hannah WN Jr1, Harrison SA2. Dig Dis Sci. 2016 May;61(5):1365-74. doi: 10.1007/s10620-016-4153-y.
 
66.Gut Microbiota and Lifestyle Interventions in NAFLD
  Houghton D1, Stewart CJ2, Day CP3,4, Trenell M5. Int J Mol Sci. 2016 Mar 25;17(4). pii: E447. doi: 10.3390/ijms17040447.
 
67.A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD
  Hossain N1, Kanwar P1, Mohanty SR1. Gastroenterol Res Pract. 2016;2016:7109270. doi: 10.1155/2016/7109270. Epub 2016 Feb 23.
 
68.Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016
  Kaswala DH1, Lai M1, Afdhal NH2. Dig Dis Sci. 2016 May;61(5):1356-64. doi: 10.1007/s10620-016-4079-4. Epub 2016 Mar 26.
 
69.Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection-Liver: The
  Ballestri S1, Nascimbeni F2,3, Romagnoli D4, Baldelli E5, Targher G6, Lonardo A7. Int J Mol Sci. 2016 Mar 9;17(3). pii: E355. doi: 10.3390/ijms17030355.
 
70.Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease
  Bedossa P1, Patel K2. Gastroenterology. 2016 Mar 19. pii: S0016-5085(16)00354-1. doi: 10.1053/j.gastro.2016.03.008. [Epub ahead of print]
 
71.Telomeres, NAFLD and Chronic Liver Disease
  Donati B1, Valenti L2. Int J Mol Sci. 2016 Mar 15;17(3). pii: E383. doi: 10.3390/ijms17030383.
 
72.Non-alcoholic fatty liver disease and liver transplantation
  Khan RS1, Newsome PN2. Metabolism. 2016 Mar 3. pii: S0026-0495(16)00052-4. doi: 10.1016/j.metabol.2016.02.013. [Epub ahead of print]
 
73.Perspectives on Treatment for Nonalcoholic Steatohepatitis
  Lassailly G1, Caiazzo R2, Pattou F2, Mathurin P3. Gastroenterology. 2016 Mar 10. pii: S0016-5085(16)00323-1. doi: 10.1053/j.gastro.2016.03.004. [Epub ahead of print]
 
74.Comparison of Doppler ultrasound and transient elastography in the diagnosis of significant fibrosis in patients with nonalcoholic steatohepatitis
  Ergelen R1, Yilmaz Y2, Asedov R3, Celikel C4, Akin H2, Bugdayci O3, Altun E5, Tuney D3. Abdom Radiol (NY). 2016 Mar 10. [Epub ahead of print]
 
75.Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes
  Lomonaco R1, Bril F2, Portillo-Sanchez P2, Ortiz-Lopez C3, Orsak B3, Biernacki D2, Lo M4, Suman A5, Weber MH6, Cusi K7. Diabetes Care. 2016 Feb 9. pii: dc151876. [Epub ahead of print]
 
76.Cost-Effectiveness Analysis: Risk Stratification of Nonalcoholic Fatty Liver Disease (NAFLD) by the Primary Care Physician Using the NAFLD Fibrosis Score
  Tapper EB1, Hunink MG2,3, Afdhal NH1, Lai M1, Sengupta N4. PLoS One. 2016 Feb 23;11(2):e0147237. doi: 10.1371/journal.pone.0147237. eCollection 2016.
 
77.Histamine H2-Receptor Antagonist Use Is Associated With Lower Prevalence of Nonalcoholic Fatty Liver Disease: A Population-based Study From the National Health and Nutrition Examination Survey, 2001-2006
  Shen H1, Liangpunsakul S. J Clin Gastroenterol. 2016 Feb 22. [Epub ahead of print]
 
78.Steatohepatitis and liver fibrosis are predicted by the characteristics of very low density lipoprotein in nonalcoholic fatty liver disease
  Jiang ZG1, Tapper EB1, Connelly MA2, Pimentel CM1, Feldbrügge L1, Kim M3, Krawczyk S3, Afdh Al N1, Robson SC1, Herman M3, Otvos JD2, Mukamal KJ4, Lai M1. Liver Int. 2016 Jan 27. doi: 10.1111/liv.13076. [Epub ahead of print]
 
79.Screening for Nonalcoholic Steatohepatitis in Individuals with Type 2 Diabetes: A Cost-Effectiveness Analysis
  Corey KE1,2, Klebanoff MJ3,4, Tramontano AC5, Chung RT6,7, Hur C8,9,10. Dig Dis Sci. 2016 Jan 29. [Epub ahead of print]
 
80.Nonalcoholic Steatohepatitis: Diagnostic Challenges
  Gill RM1, Kakar S2. Surg Pathol Clin. 2013 Jun;6(2):227-57. doi: 10.1016/j.path.2013.03.002. Epub 2013 May 4.
 
81.Is There Any Relation between the Degree of Fatty Liver Disease and Severity of Lower Urinary Tract Symptoms?
  Song YA1, Kwon SS2, Doo SW3, Kim JH4, Yang WJ3, Song YS3. Urology. 2015 Dec 9. pii: S0090-4295(15)01099-7. doi: 10.1016/j.urology.2015.11.030. [Epub ahead of print]
 
82.Circulating microRNAs in nonalcoholic fatty liver disease
  DiStefano JK1, Gerhard GS2. Expert Rev Gastroenterol Hepatol. 2015 Nov 25. [Epub ahead of print]
 
83.Clinical patterns of hepatocellular carcinoma (hcc) in non alcoholic fatty liver disease (NAFLD): A multicenter prospective study
  Piscaglia F1, Svegliati-Baroni G2, Barchetti A3, Pecorelli A1, Marinelli S1, Tiribelli C3,4, Bellentani S3; HCC-NAFLD Italian Study group. Hepatology. 2015 Nov 24. doi: 10.1002/hep.28368. [Epub ahead of print]
 
84.Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
  Armstrong MJ1, Gaunt P2, Aithal GP3, Barton D4, Hull D4, Parker R1, Hazlehurst JM5, Guo K4; LEAN trial team, Abouda G6, Aldersley MA7, Stocken D8, Gough SC5, Tomlinson JW5, Brown RM9, Hübscher SG10, Newsome PN11. Lancet. 2015 Nov 19. pii: S0140-6736(15)00803-X. doi: 10.1016/S0140-6736(15)00803-X. [Epub ahead of print]
 
85.Non-alcoholic fatty liver disease and risk of cardiovascular disease
  Lonardo A1, Sookoian S2, Pirola CJ3, Targher G4. Metabolism. 2015 Sep 25. pii: S0026-0495(15)00271-1. doi: 10.1016/j.metabol.2015.09.017. [Epub ahead of print]
 
86.Dietary approach in the treatment of nonalcoholic fatty liver disease
  Ferolla SM1, Silva LC1, Ferrari Mde L1, da Cunha AS1, Martins Fdos S1, Couto CA1, Ferrari TC1. World J Hepatol. 2015 Oct 28;7(24):2522-34. doi: 10.4254/wjh.v7.i24.2522.
 
87.The Prevalence of Non-Alcoholic Fatty Liver Disease in Children and Adolescents: A Systematic Review and Meta-Analysis
  Anderson EL1, Howe LD1, Jones HE2, Higgins JP3, Lawlor DA1, Fraser A1. PLoS One. 2015 Oct 29;10(10):e0140908. doi: 10.1371/journal.pone.0140908. eCollection 2015.
 
88.Non-alcoholic Steatohepatitis is Associated with Increased Mortality in Obese Patients Undergoing Bariatric Surgery
  Goossens N1, Hoshida Y2, Song WM3, Jung M4, Morel P4, Nakagawa S5, Zhang B3, Frossard JL6, Spahr L6, Friedman SL5, Negro F7, Rubbia-Brandt L8, Giostra E6. Clin Gastroenterol Hepatol. 2015 Oct 19. pii: S1542-3565(15)01406-8. doi: 10.1016/j.cgh.2015.10.010. [Epub ahead of print]
 
89.Nonalcoholic Steatohepatitis is the Most Rapidly Growing Indication for Simultaneous Liver Kidney Transplantation in the United States
  Singal AK1, Hasanin M, Kaif M, Wiesner R, Kuo YF. Transplantation. 2015 Oct 16. [Epub ahead of print]
 
90.Omega-3 fatty acids: Mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD
  Nobili V1, Alisi A2, Musso G3, Scorletti E4,5, Calder PC4,5, Byrne CD4,5. Crit Rev Clin Lab Sci. 2015 Oct 14:1-15. [Epub ahead of print]
 
91.Systematic review of genetic association studies involving histologically confirmed non-alcoholic fatty liver disease
  Wood KL1, Miller MH2, Dillon JF2. BMJ Open Gastroenterol. 2015 Feb 17;2(1):e000019. doi: 10.1136/bmjgast-2014-000019. eCollection 2015.
 
92.Sex-specific differences in hepatic fat oxidation and synthesis may explain the higher propensity for NAFLD in men
  Pramfalk C1, Pavlides M2,3, Banerjee R2, McNeil CA1, Neubauer S2, Karpe F1,4, Hodson L1. J Clin Endocrinol Metab. 2015 Sep 28:jc20152649. [Epub ahead of print]
 
93.Hype or Reality: Should Patients with Metabolic Syndrome-related NAFLD be on the Hunter-Gatherer (Paleo) Diet to Decrease Morbidity?
  Tarantino G1, Citro V2, Finelli C3. J Gastrointestin Liver Dis. 2015 Sep;24(3):359-68. doi: 10.15403/jgld.2014.1121.243.gta.
 
94.Nonalcoholic fatty liver disease: Current status and future directions
  Demir M1, Lang S1, Steffen HM1. J Dig Dis. 2015 Sep 25. doi: 10.1111/1751-2980.12291. [Epub ahead of print]
 
95.Nonalcoholic Fatty Liver Disease and Fibrosis in Youth Taking Psychotropic Medications: Literature Review, Case Reports, and Management
  Gracious BL1,2, Bhatt R2,3, Potter C4. J Child Adolesc Psychopharmacol. 2015 Oct 8. [Epub ahead of print]
 
96.Relevance of low testosterone to non-alcoholic fatty liver disease
  Mody A1, White D2, Kanwal F3, Garcia JM4. Cardiovasc Endocrinol. 2015 Sep 1;4(3):83-89.
 
97.The Gut Microbiota and Nonalcoholic Fatty Liver Disease
  Quigley EM1, Monsour HP1. Semin Liver Dis. 2015 Aug;35(3):262-9. doi: 10.1055/s-0035-1562946. Epub 2015 Sep 17.
 
98.Systemic Complications of Nonalcoholic Fatty Liver Disease: When the Liver Is Not an Innocent Bystander
  Vanni E1, Marengo A1, Mezzabotta L1, Bugianesi E1. Semin Liver Dis. 2015 Aug;35(3):236-49. doi: 10.1055/s-0035-1562944. Epub 2015 Sep 17.
 
99.Hepatic Injury in Nonalcoholic Steatohepatitis Contributes to Altered Intestinal Permeability
  Luther J1, Garber JJ1, Khalili H1, Dave M2, Bale SS3, Jindal R3, Motola DL1, Luther S1, Bohr S3, Jeoung SW1, Deshpande V1, Singh G4, Turner JR4, Yarmush ML3, Chung RT1, Patel SJ3. Cell Mol Gastroenterol Hepatol. 2015 Mar;1(2):222-232.
 
100.Relevance of low testosterone to non-alcoholic fatty liver disease
  Mody A1, White D2, Kanwal F3, Garcia JM4. Cardiovasc Endocrinol. 2015 Sep 1;4(3):83-89.
 
101.The Gut Microbiota and Nonalcoholic Fatty Liver Disease
  Quigley EM1, Monsour HP1. Semin Liver Dis. 2015 Aug;35(3):262-9. doi: 10.1055/s-0035-1562946. Epub 2015 Sep 17.
 
102.Systemic Complications of Nonalcoholic Fatty Liver Disease: When the Liver Is Not an Innocent Bystander
  Vanni E1, Marengo A1, Mezzabotta L1, Bugianesi E1. Semin Liver Dis. 2015 Aug;35(3):236-49. doi: 10.1055/s-0035-1562944. Epub 2015 Sep 17.
 
103.Hepatic Injury in Nonalcoholic Steatohepatitis Contributes to Altered Intestinal Permeability
  Luther J1, Garber JJ1, Khalili H1, Dave M2, Bale SS3, Jindal R3, Motola DL1, Luther S1, Bohr S3, Jeoung SW1, Deshpande V1, Singh G4, Turner JR4, Yarmush ML3, Chung RT1, Patel SJ3. Cell Mol Gastroenterol Hepatol. 2015 Mar;1(2):222-232.
 
104.The Prevalence and Presumed Etiology of Elevated Aminotransferase Levels in a Pacific Northwest Tribal Community
  Scott J, Kowdley KV, Ioannou GN, Krantz E, Lallemand O, Tsosie U, Buchwald D. J Health Care Poor Underserved. 2015;26(3):957-66. doi: 10.1353/hpu.2015.0091.
 
105.Burden of nonalcoholic fatty liver disease and advanced fibrosis in a Texas Hispanic community cohort
  Pan JJ1, Fisher-Hoch SP1, Chen C1, Feldstein AE1, McCormick JB1, Rahbar MH1, Beretta L1, Fallon MB1. World J Hepatol. 2015 Jun 18;7(11):1586-94. doi: 10.4254/wjh.v7.i11.1586.
 
106.Dysregulated Hepatic Methionine Metabolism Drives Homocysteine Elevation in Diet-Induced Nonalcoholic Fatty Liver Disease
  Pacana T1, Cazanave S1, Verdianelli A1, Patel V1, Min HK1, Mirshahi F1, Quinlivan E2, Sanyal AJ1. PLoS One. 2015 Aug 31;10(8):e0136822. doi: 10.1371/journal.pone.0136822. eCollection 2015.
 
107.Cost-Effective Evaluation of Nonalcoholic Fatty Liver Disease With NAFLD Fibrosis Score and Vibration Controlled Transient Elastography
  Tapper EB1, Sengupta N1, Hunink MG2,3, Afdhal NH1, Lai M1. Am J Gastroenterol. 2015 Sep;110(9):1298-304. doi: 10.1038/ajg.2015.241. Epub 2015 Aug 25.
 
108.Nonmedicinal interventions in nonalcoholic fatty liver disease
  Neuman MG, Nanau RM, Cohen LB. Can J Gastroenterol Hepatol. 2015 Jun-Jul;29(5):241-52.
 
109.Non-alcoholic fatty liver disease following liver transplantation: a clinical review
  Merola J1, Liapakis A2, Mulligan DC1, Yoo PS1. Clin Transplant. 2015 Sep;29(9):728-37. doi: 10.1111/ctr.12585. Epub 2015 Aug 11.
 
110.Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials
  Sato K1, Gosho M2, Yamamoto T3, Kobayashi Y3, Ishii N3, Ohashi T3, Nakade Y3, Ito K3, Fukuzawa Y3, Yoneda M3. Nutrition. 2015 Jul-Aug;31(7-8):923-30. doi: 10.1016/j.nut.2014.11.018. Epub 2014 Dec 24.
 
111.Noninvasive Assessment of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease
  Buzzetti E1, Lombardi R1, De Luca L1, Tsochatzis EA1. Int J Endocrinol. 2015;2015:343828. doi: 10.1155/2015/343828. Epub 2015 Apr 30.
 
112.Bile Acid Signaling: Mechanism for Bariatric Surgery, Cure for NASH?
  Kohli R1, Myronovych A, Tan BK, Salazar-Gonzalez RM, Miles L, Zhang W, Oehrle M, Sandoval DA, Ryan KK, Seeley RJ, Setchell KD. Dig Dis. 2015;33(3):440-6. doi: 10.1159/000371699. Epub 2015 May 27.
 
113.Trends in the Burden of Non-alcoholic Fatty Liver Disease in a US Cohort of Veterans
  Kanwal F1, Kramer JR2, Duan Z2, Yu X3, White D4, El-Serag HB5. Clin Gastroenterol Hepatol. 2015 Aug 17. pii: S1542-3565(15)01109-X. doi: 10.1016/j.cgh.2015.08.010. [Epub ahead of print]
 
114.Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
  Perumpail RB1, Wong RJ, Ahmed A, Harrison SA.

Dig Dis Sci. 2015 Aug 7. [Epub ahead of print]
 
115.Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.
  Vilar-Gomez E1, Martinez-Perez Y2, Calzadilla-Bertot L2, Torres-Gonzalez A2, Gra-Oramas B3, Gonzalez-Fabian L3, Friedman SL4, Diago M5, Romero-Gomez M6.

Gastroenterology. 2015 Aug;149(2):367-378.e5. doi: 10.1053/j.gastro.2015.04.005. Epub 2015 Apr 10.
 
116.Association of Non-alcoholic Fatty Liver Disease (NAFLD) with Hepatocellular Carcinoma (HCC) in the United States from 2004-2009
  Younossi ZM1,2,3, Otgonsuren M3, Henry L1,3, Venkatesan C2, Mishra A1, Erario M2, Hunt S1. Hepatology. 2015 Aug 14. doi: 10.1002/hep.28123. [Epub ahead of print]
 
117.NAFLD Review: Diagnosis, Treatment and Outcomes
  Ahmed A1, Wong RJ2, Harrison SA3. Clin Gastroenterol Hepatol. 2015 Jul 27. pii: S1542-3565(15)00988-X. doi: 10.1016/j.cgh.2015.07.029. [Epub ahead of print]
 
 
 
 
 
                               
 
HEPATITIS
HBV
HCV
HDV
 
 
HCC
Slide Library
Abstract Library
 
HE
Webcasts
Slide Library
Abstract Library
 
HRS
Webcasts
Slide Library
Abstract Library
 
NASH
Webcasts
Slide Library
Abstract Library
 
 
PBC
Webcasts
Slide Library
Abstract Library
 
 
THROMBOCYTOPENIA
Webcasts
Slide Library
   
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors/Faculty
2019 GI Fellow Board of Advisors
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Hepatology
Substance Use Disorder
             
CLDF Follow Us
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2021 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.